Facial erythema after the treatment of dupilumab in SLE patient.

Dong Hyek JangJae In LeeJoo Yoon BaeHye Jung JungMi Yeon ParkJi Young Ahn

Published in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2020)

Dupilumab is an emerging therapeutic agent for AD, and treatment cases are increasing in Korea. However, there are several adverse events during the treatment of dupilumab. Herein, we report the unexpected adverse event during the treatment of dupilumab in SLE patients.

Keyphrases

atopic dermatitis
systemic lupus erythematosus
end stage renal disease
chronic kidney disease
emergency department
ejection fraction
combination therapy
rheumatoid arthritis
peritoneal dialysis
replacement therapy
smoking cessation